ABILITYPHARMA

Ability Pharmaceuticals is a clinical stage drug discovery and development biopharmaceutical company

PIPELINE

ABTL0812, first-in-class, is currently in phase 2 clinical trials in lung cancer and endometrial cancer patients in Spain and France

SCIENCE

AbilityPharma investigates cancer drugs inducing autophagy by binding receptors PPARα/γ

ONE MILLION EUROS CROWDFUNDING CAMPAIGN WITH CAPITAL CELL COMPLETED

PHASE 2 CLINICAL TRIAL ONGOING AS FIRST-LINE THERAPY IN PATIENT WITH EITHER ADVANCED/METASTATIC ENDOMETRIAL CANCER OR LUNG CANCER. PATIENTS BEING RECRUITED AT VALL D'HEBRON INSTITUT D'ONCOLOGIA VHIO (BARCELONA), INSTITUT GUSTAVE ROUSSY IGR (PARIS), INSTITUT CATALÀ D'ONCOLOGIA ICO (L’HOSPITALET, BADALONA AND GIRONA), CENTRE LÉON BÉRARD (LYON), INCLIVA (VALENCIA), INSTITUT PAOLI-CALMETTES (MARSEILLE) AND HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO (SEVILLE).

AbilityPharma is a biopharmaceutical company focused on creating the future of oncology by developing innovative therapies that address unmet medical needs. The company was established in 2009 with one product, ABTL0812, an oral autophagy-inducer targeted therapy in phase 2 clinical trials in patients with endometrial cancer and in squamous NSCLC.

Media Center

05.12.2018

News

AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
07.11.2018

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
14.12.2017

Events

2018 + info
06.02.2017

Events

2017 + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG